Skip to main content
Top
Published in: BMC Health Services Research 1/2013

Open Access 01-12-2013 | Research article

Where are we now: assessing the price, availability and affordability of essential medicines in Delhi as India plans free medicine for all

Author: Anita Kotwani

Published in: BMC Health Services Research | Issue 1/2013

Login to get access

Abstract

Background

Inequitable access to medicines is a major weakness in the Indian health care system. Baseline data needed to develop effective public health policy and provide equitable access to essential medicines. The present survey was conducted to investigate the price, availability, and affordability of fifty essential medicines in the public and private sector in Delhi, India using standardized WHO/HAI methodology.

Methods

Data on procurement price and availability was collected (July-October 2011) from three public healthcare providers: the federal (central) government, state government and Municipal Corporation of Delhi (MCD). Data on price and availability of medicines was collected from private retail and chain pharmacies of a leading corporate house. Prices were compared to an international reference price (expressed as median price ratio-MPR).

Results

The procurement price of surveyed medicines was 0.53-0.82 times the international reference price-IRP. However, the overall mean availability of surveyed medicines in facilities under state government and MCD was 41.3% and 23.2%, respectively. The overall mean availability of medicines in three tertiary care facilities operated by the federal government was 49.3%. Availability of generic medicines was much higher in the private sector. Off-patented medicines, like diazepam, diclofenac, and doxycycline had the highest MPRs. The price ratio between procurement and retail was as high as 28 (range 11–28) for certain medicines. Seven-day treatment with a popular brand of amoxicillin+clavulanic acid or one inhaler each of budesonide and salbutamol cost 2.3 and 1.4 days’ wages for the lowest paid government worker. A majority of India’s population cannot afford these prices.

Conclusions

This study revealed that procurement prices of surveyed medicines were reasonable in comparison to IRP. However, variation in procurement prices of certain medicines by different public procurement agencies was noted. Availability of medicines was very poor in public sector facilities, which are the primary source of free medicines for a majority of India’s low-income population. Availability of medicines is better in private retail pharmacies but affordability remains a big challenge for a majority of the population. These data have significant policy implications that could help in amending policies to increase the access to essential medicines for India’s population.
Appendix
Available only for authorised users
Literature
1.
go back to reference Hogerzeil H: Essential medicines and human rights: what can they learn from each other?. Bull World Health Organ. 2006, 84: 371-375. 10.2471/BLT.06.031153.CrossRefPubMedPubMedCentral Hogerzeil H: Essential medicines and human rights: what can they learn from each other?. Bull World Health Organ. 2006, 84: 371-375. 10.2471/BLT.06.031153.CrossRefPubMedPubMedCentral
2.
go back to reference Perehudoff SK, Laing RO, Hogerzeil HV: Access to essential medicines in national constitutions. Bull World Health Organ. 2010, 88: 800-10.2471/BLT.10.078733.CrossRefPubMedPubMedCentral Perehudoff SK, Laing RO, Hogerzeil HV: Access to essential medicines in national constitutions. Bull World Health Organ. 2010, 88: 800-10.2471/BLT.10.078733.CrossRefPubMedPubMedCentral
5.
7.
go back to reference Creese A, Kotwani A, Kutzin J, Pillay A: Evaluating pharmaceuticals for health policy in low- and middle-income country settings. Evaluating pharmaceuticals for health policy and reimbursement. Edited by: Freemantle N, Hill S. 2004, Massachusetts, U.S.A: Blackwell Publishing (in collaboration with WHO, Geneva), 227-243.CrossRef Creese A, Kotwani A, Kutzin J, Pillay A: Evaluating pharmaceuticals for health policy in low- and middle-income country settings. Evaluating pharmaceuticals for health policy and reimbursement. Edited by: Freemantle N, Hill S. 2004, Massachusetts, U.S.A: Blackwell Publishing (in collaboration with WHO, Geneva), 227-243.CrossRef
9.
go back to reference Madden JM, Meza E, Ewen M, Laing RO, Stephens P, Ross-Degnan D: Measuring medicine prices in Peru: validation of key aspects of WHO/HAI survey methodology. Rev Panam Salud Publica. 2010, 27: 291-299. 10.1590/S1020-49892010000400008.CrossRefPubMed Madden JM, Meza E, Ewen M, Laing RO, Stephens P, Ross-Degnan D: Measuring medicine prices in Peru: validation of key aspects of WHO/HAI survey methodology. Rev Panam Salud Publica. 2010, 27: 291-299. 10.1590/S1020-49892010000400008.CrossRefPubMed
11.
go back to reference Singal G, Nanda A, Kotwani A: A comparative evaluation of price and quality of some branded versus branded-generic medicines of the same manufacturer in India. Ind J Pharmacol. 2011, 43: 131-136. 10.4103/0253-7613.77344.CrossRef Singal G, Nanda A, Kotwani A: A comparative evaluation of price and quality of some branded versus branded-generic medicines of the same manufacturer in India. Ind J Pharmacol. 2011, 43: 131-136. 10.4103/0253-7613.77344.CrossRef
12.
go back to reference Madden J: What is a median price ratio?. Essential Drug Monitor. 2003, 33: 17. Madden J: What is a median price ratio?. Essential Drug Monitor. 2003, 33: 17.
15.
go back to reference Kotwani A, Ewen M, Dey D, et al: Medicine prices and availability at six sites in India: using the WHO-HAI methodology. Ind J Med Res. 2007, 125: 645-654. Kotwani A, Ewen M, Dey D, et al: Medicine prices and availability at six sites in India: using the WHO-HAI methodology. Ind J Med Res. 2007, 125: 645-654.
16.
go back to reference Chaudhury RR, Parameswar R, Gupta U, Sharma S, Tekur U, Bapna JS: Quality medicines for the poor: experience of the Delhi programme on rational use of drugs. HPP. 2005, 20: 124-136. Chaudhury RR, Parameswar R, Gupta U, Sharma S, Tekur U, Bapna JS: Quality medicines for the poor: experience of the Delhi programme on rational use of drugs. HPP. 2005, 20: 124-136.
17.
go back to reference Kotwani A, Gurbani N, Sharma S, Chaudhury R: Insights for policymakers from a medicine price survey in Rajasthan. Ind J Med Res. 2009, 129: 451-454. Kotwani A, Gurbani N, Sharma S, Chaudhury R: Insights for policymakers from a medicine price survey in Rajasthan. Ind J Med Res. 2009, 129: 451-454.
18.
go back to reference Kotwani A: Transparency and accountability in public procurement of essential medicines in developing countries. IJUDH. 2011, 1: 15-30. Kotwani A: Transparency and accountability in public procurement of essential medicines in developing countries. IJUDH. 2011, 1: 15-30.
20.
go back to reference Cameron A, Ewen M, Ross-Degnan D, Ball D, Laing R: Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. Lancet. 2009, 373: 240-249. 10.1016/S0140-6736(08)61762-6.CrossRefPubMed Cameron A, Ewen M, Ross-Degnan D, Ball D, Laing R: Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. Lancet. 2009, 373: 240-249. 10.1016/S0140-6736(08)61762-6.CrossRefPubMed
21.
go back to reference Babar ZUD, Ibrahim MIM, Singh H, Bukahri NI, Creese A: Evaluating drug prices, availability, affordability, and price components: implications for access to drugs in Malaysia. PLoS Med. 2007, 4: 466-475.CrossRef Babar ZUD, Ibrahim MIM, Singh H, Bukahri NI, Creese A: Evaluating drug prices, availability, affordability, and price components: implications for access to drugs in Malaysia. PLoS Med. 2007, 4: 466-475.CrossRef
22.
go back to reference Yang H, Dib HH, Zhu M, Qi G, Zhang X: Prices, availability and affordability of essential medicines in rural areas of Hubei Province. HPP. 2010, 25: 219-229. Yang H, Dib HH, Zhu M, Qi G, Zhang X: Prices, availability and affordability of essential medicines in rural areas of Hubei Province. HPP. 2010, 25: 219-229.
23.
go back to reference Kotwani A: Availability, price, and affordability of asthma medicines in five Indian states. Intern J Tuber Lung Dis. 2009, 13: 574-579. Kotwani A: Availability, price, and affordability of asthma medicines in five Indian states. Intern J Tuber Lung Dis. 2009, 13: 574-579.
25.
go back to reference Kotwani A: Psychiatric medicines in India: why public healthcare facilities and a thriving generics industry cannot assure access and affordability. Internl Psychiatry. 2012, 9: 34-36. Kotwani A: Psychiatric medicines in India: why public healthcare facilities and a thriving generics industry cannot assure access and affordability. Internl Psychiatry. 2012, 9: 34-36.
26.
go back to reference Mendis S, Fukino K, Cameron A, Laing R, Filipe A, Khatib O, et al: The availability and affordability of selected essential medicines for chronic diseases in six low- and middle-income countries. Bull World Health Organ. 2007, 85: 279-288. 10.2471/BLT.06.033647.CrossRefPubMedPubMedCentral Mendis S, Fukino K, Cameron A, Laing R, Filipe A, Khatib O, et al: The availability and affordability of selected essential medicines for chronic diseases in six low- and middle-income countries. Bull World Health Organ. 2007, 85: 279-288. 10.2471/BLT.06.033647.CrossRefPubMedPubMedCentral
27.
go back to reference Chomba EN, Haworth A, Mbewe E, Atadzhanov M, Ndubani P, Kansembe H, et al: The current availability of antiepileptic drugs in Zambia: implications for the ILAE/WHO “out of the shadows” campaign. AmJTrop Med Hyg. 2010, 83: 571-574. 10.4269/ajtmh.2010.10-0100.CrossRef Chomba EN, Haworth A, Mbewe E, Atadzhanov M, Ndubani P, Kansembe H, et al: The current availability of antiepileptic drugs in Zambia: implications for the ILAE/WHO “out of the shadows” campaign. AmJTrop Med Hyg. 2010, 83: 571-574. 10.4269/ajtmh.2010.10-0100.CrossRef
28.
go back to reference Van Mourik MS, Cameron A, Ewen M, Laing RO: Availability, price and affordability of cardiovascular medicines: a comparison across 36 countries using WHO/HAI data. BMC Cardiovasc Disord. 2010, 10: 25-10.1186/1471-2261-10-25.CrossRefPubMedPubMedCentral Van Mourik MS, Cameron A, Ewen M, Laing RO: Availability, price and affordability of cardiovascular medicines: a comparison across 36 countries using WHO/HAI data. BMC Cardiovasc Disord. 2010, 10: 25-10.1186/1471-2261-10-25.CrossRefPubMedPubMedCentral
29.
go back to reference Cameron A, Roubos I, Ewen M, Mantel-Teeuwisse A, Leufkens H, Laing R: Differences in the availability of medicines for chronic and acute conditions in the public and private sectors of developing countries. Bull World Health Organ. 2011, 89: 412-421. 10.2471/BLT.10.084327.CrossRefPubMedPubMedCentral Cameron A, Roubos I, Ewen M, Mantel-Teeuwisse A, Leufkens H, Laing R: Differences in the availability of medicines for chronic and acute conditions in the public and private sectors of developing countries. Bull World Health Organ. 2011, 89: 412-421. 10.2471/BLT.10.084327.CrossRefPubMedPubMedCentral
31.
go back to reference Quick JD: Ensuring access to essential medicines in the developing countries: a framework for action. CPT. 2003, 73: 279-283. Quick JD: Ensuring access to essential medicines in the developing countries: a framework for action. CPT. 2003, 73: 279-283.
32.
go back to reference Holloway K: Combating inappropriate use of medicines. Expert Rev Clin Pharmacol. 2011, 4: 335-348. 10.1586/ecp.11.14.CrossRefPubMed Holloway K: Combating inappropriate use of medicines. Expert Rev Clin Pharmacol. 2011, 4: 335-348. 10.1586/ecp.11.14.CrossRefPubMed
33.
go back to reference Kotwani A: Tracking medicine prices in the supply chain: who really benefits from the free market in India?. Econ Pol Wkly. 2013, Accepted for publication Kotwani A: Tracking medicine prices in the supply chain: who really benefits from the free market in India?. Econ Pol Wkly. 2013, Accepted for publication
37.
go back to reference Horton R, Das P: Indian health: the path from crisis to progress. Lancet. 2011, 377: 181-183. 10.1016/S0140-6736(10)62179-4.CrossRefPubMed Horton R, Das P: Indian health: the path from crisis to progress. Lancet. 2011, 377: 181-183. 10.1016/S0140-6736(10)62179-4.CrossRefPubMed
38.
go back to reference Niëns LM, Cameron A, Van de Poel E, Ewen M, Brouwer WBF, Laing R: Quantifying the impoverishing effects of purchasing medicines: a cross-country comparison of the affordability of medicines in the developing world. PLoS Med. 2010, 7: 1-8.CrossRef Niëns LM, Cameron A, Van de Poel E, Ewen M, Brouwer WBF, Laing R: Quantifying the impoverishing effects of purchasing medicines: a cross-country comparison of the affordability of medicines in the developing world. PLoS Med. 2010, 7: 1-8.CrossRef
39.
go back to reference Kanavos P, Costa-Font J, Seeley E: Competition in off-patent drug markets: Issues regulation and evidence. Economic Policy. 2008, 23: 499-544. 10.1111/j.1468-0327.2008.00207.x.CrossRef Kanavos P, Costa-Font J, Seeley E: Competition in off-patent drug markets: Issues regulation and evidence. Economic Policy. 2008, 23: 499-544. 10.1111/j.1468-0327.2008.00207.x.CrossRef
40.
go back to reference Joncheere K, Rietveld AH, Huttin C: Experiences with generics. Drugs and Money. Edited by: Dukes FM, Haaijer-Ruskamp CP, Joncheere A, Rietveld H. 2002, The Netherlands: Published on behalf of WHO-Europe, 101-110. IOS Press, 7 Joncheere K, Rietveld AH, Huttin C: Experiences with generics. Drugs and Money. Edited by: Dukes FM, Haaijer-Ruskamp CP, Joncheere A, Rietveld H. 2002, The Netherlands: Published on behalf of WHO-Europe, 101-110. IOS Press, 7
42.
go back to reference Ewen M: Sound price data-sound price policies. Essential drug monitor. 2003, 33: 23. Ewen M: Sound price data-sound price policies. Essential drug monitor. 2003, 33: 23.
Metadata
Title
Where are we now: assessing the price, availability and affordability of essential medicines in Delhi as India plans free medicine for all
Author
Anita Kotwani
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Health Services Research / Issue 1/2013
Electronic ISSN: 1472-6963
DOI
https://doi.org/10.1186/1472-6963-13-285

Other articles of this Issue 1/2013

BMC Health Services Research 1/2013 Go to the issue